Mochida Pharmaceutical Co., Ltd.
First Quarter Financial Summary for Period Ending March 2027 (Japanese GAAP) (Consolidated)
In the first quarter of the fiscal year ending March 2027, net sales were 31.719 billion yen, up 19.1% year over year. Operating income was 3.564 billion yen (+38.5%), ordinary income was 4.187 billion yen (+50.5%), and net income attributable to owners of the parent was 3.178 billion yen (+67.8%), marking a substantial year-over-year rise. The full-year forecast remains unchanged from the previous disclosure. The expected dividend is 42.5 yen per share at the end of the term and 85 yen for the full year.
Key Figures
- Sales: 31,719 million yen (YoY +19.1%)
- Operating income: 3,564 million yen (YoY +38.5%)
- Ordinary income: 4,187 million yen (YoY +50.5%)
- Net income attributable to owners of the parent: 3,178 million yen (YoY +67.8%)
- Earnings per share (quarter): 89.77 yen
- Dividend policy: 2027 fiscal year results/forecast Final dividend 42.50 yen, Full-year 85.00 yen
AI要約
Overview of Performance
Against a backdrop of pharmaceutical pricing revisions and rising raw material costs in the domestic drug market, the first quarter of the fiscal year ending March 2027 achieved net sales of 31,719 million yen (YoY +19.1%), a marked revenue growth. The pharmaceutical-related business contributed to the sales increase through the expansion of new drugs, and the healthcare segment showed solid growth. Operating income was 3,564 million yen (+38.5%), ordinary income was 4,187 million yen (+50.5%), and net income attributable to owners of the parent was 3,178 million yen (+67.8%). R&D expenses were 2,470 million yen, with ongoing development in drug discovery, cellular therapies, and biomaterials.
Outlook and Financial Position
The full-year forecast remains unchanged from the level announced on May 15, 2026. Total assets are 181,422 million yen, with a shareholders’ equity ratio of 77.3%, and slight fluctuation in equity attributable to shareholders due to treasury stock acquisitions. The dividend policy assumes no interim dividends in Q1 or Q2, with an expected final dividend of 42.50 yen and a full-year total of 85.00 yen. Under the mid-term growth plan 25-27 centered on new drugs, the company plans to continue strengthening core business profitability and investing in growth.
Chitose Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
